NCT06394518View on ClinicalTrials.gov

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

February 24, 2023

Study Completion Date

February 24, 2023

Conditions
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)Prosthetic Joints Infection (PJI)
Interventions
DRUG

TNP-2092 for injection

The study had 3 dose groups, a 200 mg single dose group (low-dose group), a 300 mg single and multiple dose continuous dose group (medium-dose group), and 400 mg single dose group (high-dose group)

DRUG

placebo

The placebo for TNP-2092 active drug

Trial Locations (1)

Unknown

Huashan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors
lead

TenNor Therapeutics Inc.

INDUSTRY